Advanced Magnetics, Inc.

Website: http://www.advancedmagnetics.com

NCI, through CIP, holds clinical trials agreements with Advanced Magnetics, Inc., to study two novel nanoparticle magnetic resonance contrast agents, ferumoxytol and ferumoxtran-10 (Combidex®), which were developed by the company. An exploratory clinical trial with ferumoxytol in patients with brain cancer was completed in 2005, and another exploratory clinical trial is ongoing in patients with prostate and breast cancer. CIP has also initiated a phase II study evaluating the role of ferumoxtran-10 in detecting tumor spread in axillary lymph nodes. A multi-center trial with ferumoxtran-10 for staging patients with cervical cancer is in the final stages of planning and is expected to commence in 2006.